Abstract Number: 2110 • ACR Convergence 2022
Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
Background/Purpose: The Phase 3b COSMOS study (NCT03796858) demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor, in patients (pts) with psoriatic…Abstract Number: 2114 • ACR Convergence 2022
Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study
Background/Purpose: Patients (pts) with PsA experience lower quality of life than both the general population and pts with psoriasis alone1,2. Recent PsA treatment recommendations highlight…Abstract Number: 2115 • ACR Convergence 2022
Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study
Background/Purpose: Guselkumab (GUS), an IL-23p19 inhibitor, has demonstrated efficacy in PsA across key Group for Research and Assessment of Psoriasis (PsO) and Psoriatic Arthritis (GRAPPA)-recommended…Abstract Number: 2109 • ACR Convergence 2022
Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Background/Purpose: Sustained minimal disease activity (MDA) is only achieved by a small portion of PsA patients (pts). Levels of disease activity consistent with MDA may…Abstract Number: 2032 • ACR Convergence 2022
Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome
Background/Purpose: To assess major salivary gland involvement by ultrasonography and elastography in patients with Sjögren's syndrome , compare it with controls and correlate the severity…Abstract Number: 2056 • ACR Convergence 2022
Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis
Background/Purpose: Many clinicians use belimumab as a maintenance therapy of SLE, but there is scarce data on belimumab drug retention rate and safety/effectiveness profile in…Abstract Number: 2101 • ACR Convergence 2022
Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study
Background/Purpose: Autoimmune Hemolytic Anemia (AIHA) is one of the manifestations of Systemic lupus erythematosus (SLE), an autoimmune connective tissue disease. AIHA may be present in…Abstract Number: 1998 • ACR Convergence 2022
Effect of a Lifestyle Program Based on a Whole Food Plant-based Diet, Physical Activity, and Stress Management in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial
Background/Purpose: Lifestyle factors have been associated with the development and progression of rheumatoid arthritis. Interventions involving whole food plant-based diets (1-3), physical activity (4) or…Abstract Number: 1487 • ACR Convergence 2022
Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23
Background/Purpose: Clinically relevant differences between therapeutic antibodies against the same target may relate to their unique molecular attributes. Differences in therapeutic profiles across the domains…Abstract Number: 2088 • ACR Convergence 2022
Achieving Systemic Lupus Erythematosus Disease Control or Low Lupus Disease Activity State Is Associated with Lower Rates of Organ Damage: Results from the Hopkins Lupus Cohort
Background/Purpose: The treatment target for systemic lupus erythematosus (SLE) is remission or, if this cannot be reached, the lowest disease activity achievable with the least…Abstract Number: 2112 • ACR Convergence 2022
Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Background/Purpose: Guselkumab (GUS) is associated with robust and sustained improvement in PsA signs and symptoms in subgroups of patients (pts) pooled from the phase 3…Abstract Number: 2097 • ACR Convergence 2022
Association of Renal Biopsy NIH Activity and Chronicity Scores with Clinical Outcomes in a Cohort of Patients with Lupus Nephritis
Background/Purpose: Renal biopsy has long been the gold standard for diagnosis of lupus nephritis (LN), and pathologic features on biopsy are commonly used to guide…Abstract Number: 2065 • ACR Convergence 2022
Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
Background/Purpose: B cell targeting agents (BCA), including belimumab (BEL) and rituximab (RTX), have been used with success in lupus nephritis (LN) patients, though identifying patients…Abstract Number: 2038 • ACR Convergence 2022
Single Cell RNA Sequencing Points to a Role for Fibroblasts Early in Salivary Gland Dysfunction in Primary Sjögren’s Syndrome
Background/Purpose: Salivary gland (SG) dysfunction is commonly associated with the autoimmune disease primary Sjögren's syndrome (pSS). Whilst the more advanced stages of the disease are…Abstract Number: 2040 • ACR Convergence 2022
Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study
Background/Purpose: Metformin (dimethyl biguanide, Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In vitro studies and human trials in…
- « Previous Page
- 1
- …
- 423
- 424
- 425
- 426
- 427
- …
- 2425
- Next Page »